Boothbay Fund Management, LLC Viridian Therapeutics, Inc.\De Transaction History
Boothbay Fund Management, LLC
- $5.7 Billion
- Q3 2025
A detailed history of Boothbay Fund Management, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 83,594 shares of VRDN stock, worth $2.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
83,594
Previous 182,452
54.18%
Holding current value
$2.4 Million
Previous $2.55 Million
29.49%
% of portfolio
0.03%
Previous 0.06%
Shares
5 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
81.6MCall Options Held
39.6KPut Options Held
94.3K-
Deep Track Capital, LP Greenwich, CT5.38MShares$155 Million3.65% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$137 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$127 Million8.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$125 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$112 Million12.69% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $1.15B
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...